Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of MEDI0618, a pH-sensitive monoclonal antibody aimed at PAR2, in preclinical migraine models

  • By

  • Caroline M Kopruszinski

  • John E Linley

  • Peter Thornton

  • Alison S Walker

  • Philip Newton

  • Sadhana Podichetty

  • Radhey Hemendra Ruparel

  • Luiz Henrique Moreira de Souza

  • Edita Navratilova

  • Guy Meno-Tetang

  • Ian Gurrell

  • David W Dodick

  • Claire Dobson

  • Tharani Chessell

  • Frank Porreca

  • Iain Chessell

  • February 28, 2025

Share

Original Source(s)

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

  • by Caroline M Kopruszinski, John E Linley, Peter Thornton, Alison S Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W Dodick, Claire Dobson, Tharani Chessell, Frank Porreca, Iain Chessell

  • February 28, 2025

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

MRI May Define Two Distinct Migraine Phenotypes

Patients with greater migraine burden showed widespread connectivity changes and lower cortical volume.

Exercise may protect memory after sleep loss

A 20-minute exercise bout and 90-minute nap produced similar episodic memory performance following 30 hours of wakefulness but engaged distinct neural mechanisms.